Antibody discovery market to reach $15.79 billion by 2030

By AI, Created 11:10 AM UTC, May 20, 2026, /AGP/ – The Business Research Company says the antibody discovery market is set to grow from $9.78 billion in 2025 to $15.79 billion by 2030 as demand rises for precision therapeutics, biologics and AI-driven drug discovery. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - Antibody discovery is becoming more important as drugmakers push targeted therapies and personalized medicine. - The market is expanding alongside higher R&D spending, stronger biotech infrastructure and broader use of AI and machine learning in discovery. - The growth outlook signals more investment in biologics, immunotherapy and advanced screening tools.

What happened: - The Business Research Company projected the global antibody discovery market will rise from $9.78 billion in 2025 to $10.75 billion in 2026. - The report forecast the market will reach $15.79 billion by 2030. - The report put 2025-2026 growth at a 9.8% compound annual growth rate and 2026-2030 growth at 10.1%. - The company published the market outlook on May 7, 2026, from London. - The company offered a free sample of the report and a full market report.

The details: - The report identified increased R&D investments, rising infectious and chronic disease prevalence, hybridoma technology advances, government biotech support and academic-pharma collaborations as major recent growth drivers. - The report said future growth will be supported by personalized medicine demand, AI and machine learning in drug discovery, growth in the biologics market, high-throughput screening and greater focus on immunotherapy and targeted therapies. - Emerging trends highlighted in the report include high-throughput screening, monoclonal antibodies, personalized antibody therapeutics, multi-specific antibody technologies and synthetic antibody engineering. - Antibody discovery refers to identifying and developing antibodies, which are immune proteins that recognize and bind to antigens such as bacteria or viruses. - The report said precision therapeutics is a key market driver because antibody discovery helps create therapies that act on disease-associated molecules or cells. - IQVIA Holdings reported in March 2024 that global spending on cell and gene therapies reached $5.9 billion in 2023, up 38% from 2022. - The report covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - North America’s lead suggests the region remains the center of biotech capital and innovation. - Asia-Pacific’s faster projected growth points to rising demand for advanced therapies and expanding scientific capacity outside the U.S. and Europe. - The report’s emphasis on AI, ML and high-throughput methods shows how discovery platforms are shifting toward speed and scale.

What’s next: - The market is expected to keep expanding through 2030 as biologics and personalized medicine gain share in drug development. - The report points to more use of AI-enabled discovery, multi-specific antibodies and synthetic engineering as the next wave of innovation. - Asia-Pacific will be the region to watch for the fastest growth over the forecast period.

The bottom line: - Antibody discovery is moving from a specialized research area into a faster-growing pillar of modern drug development, with the strongest momentum coming from precision medicine and technology-led discovery.